Sandbox2: Difference between revisions
No edit summary |
No edit summary |
||
Line 48: | Line 48: | ||
</div>}} | </div>}} | ||
{{familytree | | | | | | | | | | | | | |!| | | | | | || | |}} | {{familytree | | | | | | | | | | | | | |!| | | | | | || | |}} | ||
{{familytree | | | | | | | | {{familytree | | | | | | | | | |,|-|-|-|^|-|-|-|.| | | | |}} | ||
{{familytree | | | | {{familytree | | | | | | | | | D01 | | | | | | D02 | | | | D01= '''Stable patient'''| D02= '''Unstable patient'''}} | ||
{{familytree | | | | | {{familytree | | | | | | | | | |!| | | | | | | |!| | | | }} | ||
{{familytree | | | | {{familytree | | | | | | | | | E01 | | | | | | E02 | | | | E01=❑ Assess the [[ECG]] | E02=❑ Urgent electrical [[cardioversion]]}} | ||
{{familytree | | | | | | |!| | | | | | | }} | {{familytree | | | | | | | | | |!| | | | | | | }} | ||
{{familytree | | |,|-|-|-|^|-|-|-|.| | | | | }} | {{familytree | | | | | |,|-|-|-|^|-|-|-|.| | | | | }} | ||
{{familytree | | F01 | | | | | | F02 | | | | | F01=<div style="float: left; text-align: left;"> '''Orthodromic AVRT''' <br> | {{familytree | | | | | F01 | | | | | | F02 | | | | | F01=<div style="float: left; text-align: left;"> '''Orthodromic AVRT''' <br> | ||
The impulse travels from the atrium to the ventricle through the AV node and returns to the atrium through the accesory pathway. 90-95% of [[WPW]] | The impulse travels from the atrium to the ventricle through the AV node and returns to the atrium through the accesory pathway. 90-95% of [[WPW]] | ||
❑ Narrow QRS complexes <br> | ❑ Narrow QRS complexes <br> | ||
Line 62: | Line 62: | ||
</div>| | </div>| | ||
F02=<div style="float: left; text-align: left;"> '''Antidromic AVRT''' <br> | F02=<div style="float: left; text-align: left;"> '''Antidromic AVRT''' <br> | ||
The impulse travels from the atrium to the ventricle through the | The impulse travels from the atrium to the ventricle through theaccesory pathway and from the ventricle to the atrium through the AV node. Less than 10% of [[WPW]] | ||
❑ Wide QRS complexes <br> | ❑ Wide QRS complexes <br> | ||
Line 68: | Line 68: | ||
❑ Short PR interval more than one half of the tachycardia RR interval | ❑ Short PR interval more than one half of the tachycardia RR interval | ||
</div> }} | </div> }} | ||
{{familytree | | | | | |!| | | | | | | |!| | | | | |}} | |||
{{familytree | | | | | G01 | | | | | | G02 | | | | G01=<div style="float: left; text-align: left;"> '''Treatment.'''<ref name="Mehta-1988">{{Cite journal | last1 = Mehta | first1 = D. | last2 = Wafa | first2 = S. | last3 = Ward | first3 = DE. | last4 = Camm | first4 = AJ. | title = Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. | journal = Lancet | volume = 1 | issue = 8596 | pages = 1181-5 | month = May | year = 1988 | doi = | PMID = 2897005 }}</ref><ref name="Jackman-1988">{{Cite journal | last1 = Jackman | first1 = WM. | last2 = Friday | first2 = KJ. | last3 = Fitzgerald | first3 = DM. | last4 = Yeung-Lai-Wah | first4 = JA. | last5 = Lazzara | first5 = R. | title = Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia. | journal = Am J Cardiol | volume = 62 | issue = 19 | pages = 8L-19L | month = Dec | year = 1988 | doi = | PMID = 3059792 }}</ref><ref name="Sung-1980">{{Cite journal | last1 = Sung | first1 = RJ. | last2 = Elser | first2 = B. | last3 = McAllister | first3 = RG. | title = Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. | journal = Ann Intern Med | volume = 93 | issue = 5 | pages = 682-9 | month = Nov | year = 1980 | doi = | PMID = 7212475 }}</ref><br> | |||
❑ Use [[Valsalva maneuver|Valsalva maneuvers]] <br><br>''If not effective initiate IV AV nodal blocking agent''<br><br> | |||
❑ Administer [[Adenosine]]<br><br>''If not effective''<br><br> | |||
❑ Administer [[Verapamil]]<br><br>''If not effective''<br><br> | |||
❑ Administer [[Procainamide]]<br> | |||
</div> | | |||
G02=<div style="float: left; text-align: left;"> '''Treatment.'''<br> | |||
❑ Administration of [[Procainamide]], [[Flecainide]] or [[Ibutilide]] is the prefered treatment<br> | |||
❑ [[Adenosine]] should be used with caution because may produce [[AF]]<br> | |||
</div>}} | |||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 16:07, 17 March 2014
|
Overview
Wolff-Parkinson-White syndrome (WPW) is a syndrome of pre-excitation of the ventricles of the heart due to an accessory pathway known as the Bundle of Kent.
Causes
Life Threatening Causes
Life-threatening causes include conditions which result in death or permanent disability within 24 hours if left untreated. Wolff-Parkinson-White syndrome can be a life-threatening condition and must be treated as such irrespective of the underlying cause.
Common Causes
WPW is a congenic disease
Managment
Initial Management
Shown below is an algorithm summarizing the initial management of supraventricular tachycardia according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.[1]
AVRT: AV reentrant tachycardia
Characterize the symptoms:
Characterize the timing of the symptoms: | |||||||||||||||||||||||||||||||||||||||||||||||
Identify possible triggers: | |||||||||||||||||||||||||||||||||||||||||||||||
❑ Examine the patient
❑ Order and monitor the ECG | |||||||||||||||||||||||||||||||||||||||||||||||
Stable patient | Unstable patient | ||||||||||||||||||||||||||||||||||||||||||||||
❑ Assess the ECG | ❑ Urgent electrical cardioversion | ||||||||||||||||||||||||||||||||||||||||||||||
Orthodromic AVRT The impulse travels from the atrium to the ventricle through the AV node and returns to the atrium through the accesory pathway. 90-95% of WPW ❑ Narrow QRS complexes | Antidromic AVRT The impulse travels from the atrium to the ventricle through theaccesory pathway and from the ventricle to the atrium through the AV node. Less than 10% of WPW ❑ Wide QRS complexes | ||||||||||||||||||||||||||||||||||||||||||||||
Treatment.[2][3][4] ❑ Use Valsalva maneuvers | Treatment. ❑ Administration of Procainamide, Flecainide or Ibutilide is the prefered treatment | ||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.
- ↑ Mehta, D.; Wafa, S.; Ward, DE.; Camm, AJ. (1988). "Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia". Lancet. 1 (8596): 1181–5. PMID 2897005. Unknown parameter
|month=
ignored (help) - ↑ Jackman, WM.; Friday, KJ.; Fitzgerald, DM.; Yeung-Lai-Wah, JA.; Lazzara, R. (1988). "Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia". Am J Cardiol. 62 (19): 8L–19L. PMID 3059792. Unknown parameter
|month=
ignored (help) - ↑ Sung, RJ.; Elser, B.; McAllister, RG. (1980). "Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations". Ann Intern Med. 93 (5): 682–9. PMID 7212475. Unknown parameter
|month=
ignored (help)